Pulmonx Corporation (LUNG)
Pulmonx Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Pulmonx Corporation (LUNG) is a Medical - Devices company based in US with a market capitalization of $70M. Revenue grew 8.0% year-over-year and free cash flow was negative at -$32.9M. This page tracks LUNG's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 291 employees · IPO Oct 1, 2020
Valuation
Valuation & price
$1.27as of May 17, 2026· -66.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.29
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$70M
Market cap
8.0%
Revenue growth (YoY)
74.2%
Gross margin
-$32.9M
Free cash flow (USD)
-$13.6M
Net debt
Net cash position
4.0%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 4, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 4, 2026Filing
Annual Meeting Results
- Insider sellJun 3, 2026Filing
Insider Sell $87KFrench Glendon E. III · Director, President and CEO · $86.9K
- Insider sellJun 3, 2026Filing
Insider Sell $12KRose Geoffrey Beran · CHIEF COMMERCIAL OFFICER · $12.4K
- Insider sellJun 3, 2026Filing
Insider Sell $22KLehman David Aaron · GENERAL COUNSEL · $22.5K
- Insider sellJun 3, 2026Filing
Insider Sell $22KRadhakrishnan Srikanth · Chief Science &Techn. Officer · $22.3K
- Quarterly reportMay 4, 2026Filing
10-Q Filed
- 8-K eventApr 29, 2026Filing
Earnings Release
Questions
Frequently asked questions
What is Pulmonx Corporation's market cap?
Pulmonx Corporation (LUNG) has a market capitalization of $70M.
What is LUNG's P/E ratio?
A meaningful P/E ratio is not available for LUNG — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LUNG's price-to-book (P/B) ratio?
LUNG trades at 1.29 times book value per share.
Are insiders buying LUNG stock?
SEC Form 4 filings show no open-market insider buys at Pulmonx Corporation in the last 90 days (4 sells).
Same arena
Related companies in Medical - Devices
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.